Arthritis in Medical Technology

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who had failed to respond to at ... (MRI) and scored using the RAMRIS (Rheumatoid arthritis Magnetic Resonance Imaging Scoring) system. ... ------ * RAMRIS is a rheumatoid arthritis scoring system utilizing magnetic resonance ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis ... the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in the European ...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

... disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely ... and Attenuates Progression of Experimental arthritis . The authors of the article included members of ... for clinical development of PR-957 in rheumatoid arthritis and other inflammatory and autoimmune diseases," ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor ... achieved at least a 20 percent improvement in arthritis symptoms (ACR 20) at week 14, compared with 18 ... has shown promise in the treatment of rheumatoid arthritis patients who have previously discontinued other ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... the signs and symptoms in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ... ACR 20. At least 50 percent improvement in arthritis signs and symptoms (ACR 50) was seen in 47 of 70 ... in the signs and symptoms of psoriatic arthritis through two years of treatment," said Iain B. ...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June ... that a greater proportion of rheumatoid arthritis (RA) patients treated with ACTEMRA(R) ... for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile ...

Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain

... written each year for the treatment of arthritis and other types of mild-to-moderate pain. ... risk of NSAID-induced ulcers. About the arthritis and Pain Market According to the arthritis ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... damage to joints in patients with rheumatoid arthritis (RA). The study also showed that patients ... for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan. ACTEMRA (known as ...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

... trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its ... and novel treatment option for rheumatoid arthritis and potentially other inflammatory indications." ... 2 study." About MDX-1100 in Rheumatoid arthritis MDX-1100 is a fully human antibody that ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... with moderately to severely active rheumatoid arthritis and moderate to severe Crohn's disease, to U.S. ... UCB partnership with OXO(R) -- Rheumatoid arthritis patients directly involved with UCB and OXO(R) in ... easy for people living with rheumatoid arthritis ATLANTA, May 14 /PRNewswire/ -- In a ...

Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain

... suffer from the aches and pains that come with arthritis and other chronic joint problems(1). One of the most effective ways to get fast relief from arthritis pain is the use of analgesic creams. The only ... arthritis, all of whom had had a history of daily arthritis pain for a minimum of six months. For ten days, ...

Staying One Step Ahead of Osteoporosis

... 20 percent men, who were affected by rheumatoid arthritis and under Vitamin D supplementation. "We wanted ... "We found that women affected by rheumatoid arthritis for more than three years were osteoporotic and ... study faired much better. Those with rheumatoid arthritis did not have a significant risk of fracture. ...

Got Pain?

... Common hand and finger problems can include arthritis in the base of the thumb, Dupuytren's Disease (a ... and get patients back to full function. arthritis of the Base of the Thumb and Finger ( ... Dr. Osterman concluded that "injuries, arthritis and aging affect hand mobility and these newer ...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

... conditions or diagnosis of inflammatory arthritis or autoimmune disorders; and with no invasive ... RC, et al. Estimates of the Prevalence of arthritis and Other Rheumatic Conditions in the United States. 2008. arthritis and Rheumatism (58):26-35. (3) National ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

... with moderately to severely active rheumatoid arthritis (RA). As a result of the FDA's evolving ... compared with DMARDs alone. On July 29, 2008, the arthritis Advisory Committee of the FDA voted 10-1 to ... of moderately severe to severe, active rheumatoid arthritis in adult patients who did not respond adequately ...

Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

... in the second half of 2009. About the arthritis and Pain Market According to the arthritis Foundation, arthritis affects 46 million people in United States and ...

Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout

... Center, Inc., U.S., announced today that the arthritis Advisory Committee of the U.S. Food and Drug ... recommendation. "Today's vote by the arthritis Advisory Committee, recommending approval of ... Gout is the most common inflammatory arthritis in men over age 40. According to the National ...

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients

... for the following indications: Rheumatoid arthritis Enbrel in combination with methotrexate ... treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying ... of severe, active and progressive rheumatoid arthritis in adults not previously treated ...

Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

... have been published in the November 2008 issue of arthritis and Rheumatism. The article, entitled, "Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, ... enrolled 189 patients with active rheumatoid arthritis (RA) already taking methotrexate for their ...

CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years

... in relieving symptoms of rheumatoid arthritis (RA) through 100 weeks. Another analysis ... improvement on the Patients Assessment of arthritis Pain (PAAP) scale, the data showed an average ... rates. About Rheumatoid Arthritis Rheumatoid arthritis (RA) is a progressive autoimmune disease ...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

... joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study ... rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan. The serious ...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

... debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs ... About the RADIATE Study RADIATE (RheumAtoiD arthritis Study in Anti-TNF FailurEs), a ... rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile ...

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

... in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's ... disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

... Duration of Disease, Diagnosis of Psoriatic arthritis or Recent Systemic Therapy PARIS, Sept. 18 ... whether the patient has a diagnosis of psoriatic arthritis (PsA), or if he or she has a recent history of ... increased background lymphoma risk in rheumatoid arthritis patients with long-standing, highly ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... announced today that it presented new rheumatoid arthritis data at the Marcus Evans conference on ... the permanent tissue damage caused by rheumatoid arthritis in an animal model of the disease. These ... parameters that can be seen in rheumatoid arthritis damage in humans. CEL-2000 was as good as, and ...

New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis

... Within Our Reach: Finding a Cure for Rheumatoid arthritis campaign. Doctors and scientists from across ... a Cure for Rheumatoid Arthritis Rheumatoid arthritis affects an estimated 1.3 million Americans, ... continues." To learn more about rheumatoid arthritis and the campaign, please visit ...

Pediatric Researchers Find Possible 'Master Switch' Gene in Juvenile Arthritis

... play a role in some varieties of adult rheumatoid arthritis is also present in all types of childhood ... between the gene region and juvenile idiopathic arthritis (JIA), formerly called juvenile rheumatoid ... The study appears in the July 2008 issue of arthritis & Rheumatism. Lead authors are Terri H. Finkel, ....

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

... chronic and debilitating effects of rheumatoid arthritis (RA) -- despite treatment with current therapies ... About RADIATE Study The RADIATE (RheumAtoiD arthritis Study in Anti-TNF FailurEs) trial, a three-arm, ... for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile ...

Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology

... and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including ... Study Details 127 patients with inflammatory arthritis received a single intra-articular injection of ... the data collected in the inflammatory arthritis study, the potential efficacy of tgAAC94, the ...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

... in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function and ... studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis. In the study, ... director of the Rebecca MacDonald Centre for arthritis & Autoimmune Disease at Mount Sinai Hospital in ...

New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease

... in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's ... disease, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis for a long time, particularly ...

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

... certain autoimmune diseases such as rheumatoid arthritis (RA), as well as other inflammatory diseases. ... of inflammatory cells leading to rheumatoid arthritis and subsequently joint destruction. "CCX354 is ... preclinical programs. About Rheumatoid arthritis and CCX354 ...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

... damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an ... of rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis in Japan. The serious adverse events reported ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

... active polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used as monotherapy or ... use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra. This ... as MTX or TNF antagonists. "Juvenile idiopathic arthritis is the most prevalent form of arthritis in ...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

... significant because we know that many rheumatoid arthritis patients continue to experience symptoms of ... April 2006, additional indications for rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis were also filed in Japan and are currently under ...

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis

... experience beginning with rheumatoid arthritis patients. It was approved for moderate to severe rheumatoid arthritis in 2002, psoriatic arthritis in 2005, ankylosing ... arthritis, which combines skin symptoms with arthritis symptoms, including joint pain and inflammation. ...

Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)

... ATLANTA, Dec. 11 /PRNewswire-USNewswire/ -- The arthritis Foundation, the leading health organization ... be the national presenting sponsor of the 2008 arthritis Walk (R). "The arthritis Foundation hosts hundreds ...

Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342

... The IND for the treatment of rheumatoid arthritis is for a randomized, single-dose, ... development, are effective in treating rheumatoid arthritis and various B-cell malignancies, and show promise ... than two million Americans suffer from rheumatoid arthritis (RA), a chronic autoimmune disease that develops ...

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

... to treat rheumatoid arthritis - NUTLEY, N.J., Nov. 21 /PRNewswire/ -- Roche ... in adults with moderate to severe rheumatoid arthritis (RA). "The filing for ACTEMRA represents a ... for RA and systemic-onset juvenile idiopathic arthritis were also filed in Japan in April 2006 and are ...

Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms

... improved the signs and symptoms of rheumatoid arthritis (RA) patients who failed to adequately respond ... April 2006, additional indications for rheumatoid arthritis and systemic-onset juvenile idiopathic ... patients treated with ACTEMRA. About Rheumatoid arthritis ...